tradingkey.logo
tradingkey.logo
Search

Lilly's Orforglipron Shows Superior Weight Loss And Blood Sugar Control

ReutersSep 17, 2025 1:37 PM
facebooktwitterlinkedin

- Eli Lilly and Co LLY.N:

  • POSITIVE TOPLINE RESULTS FROM ACHIEVE-3 EVALUATING SAFETY & EFFICACY OF ORFORGLIPRON VERSUS ORAL SEMAGLUTIDE

  • ORFORGLIPRON MET PRIMARY, ALL KEY SECONDARY ENDPOINTS ACROSS EACH DOSE COMPARISON VERSUS ORAL SEMAGLUTIDE

  • FOR PRIMARY ENDPOINT, ORFORGLIPRON LOWERED A1C BY 2.2% VERSUS 1.4% WITH ORAL SEMAGLUTIDE AT HIGHEST DOSES

  • PARTICIPANTS TAKING HIGHEST DOSE OF ORFORGLIPRON LOST AVERAGE 19.7 LBS VERSUS 11 LBS WITH ORAL SEMAGLUTIDE, IN KEY SECONDARY ENDPOINT

  • OVERALL SAFETY & TOLERABILITY PROFILE OF ORFORGLIPRON IN ACHIEVE-3 CONSISTENT WITH PREVIOUS TRIALS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI